Synthesis and pharmacology of proteasome inhibitors

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Andreas Rentsch
  • Dirk Landsberg
  • Tobias Brodmann
  • Leila Bülow
  • Anna Katharina Girbig
  • Markus Kalesse

Research Organisations

External Research Organisations

  • Helmholtz Centre for Infection Research (HZI)
View graph of relations

Details

Original languageEnglish
Pages (from-to)5450-5488
Number of pages39
JournalAngewandte Chemie - International Edition
Volume52
Issue number21
Publication statusPublished - 17 May 2013

Abstract

Shortly after the discovery of the proteasome it was proposed that inhibitors could stabilize proteins which ultimately would trigger apoptosis in tumor cells. The essential questions were whether small molecules would be able to inhibit the proteasome without generating prohibitive side effects and how one would derive these compounds. Fortunately, "Mother Nature" has generated a wide variety of natural products that provide distinct selectivities and specificities. The chemical synthesis of these natural products finally provided access to analogues and optimized drugs of which two different classes have been approved for the treatment of malignancies. Despite these achievements, additional lead structures derived from nature are under investigation and will be discussed with regard to their biological potential and chemical challenges. The ubiquitin-proteasome system controls fundamental processes such as cell cycle regulation, DNA repair, apoptosis, and immune and inflammatory responses, as well as hereditary disorders such as cystic fibrosis. This Review covers the synthesis of the most important proteasome inhibitors as well as their mode of action and clinical development.

Keywords

    antitumor agents, clinical development, inhibitors, natural products, proteasome

ASJC Scopus subject areas

Cite this

Synthesis and pharmacology of proteasome inhibitors. / Rentsch, Andreas; Landsberg, Dirk; Brodmann, Tobias et al.
In: Angewandte Chemie - International Edition, Vol. 52, No. 21, 17.05.2013, p. 5450-5488.

Research output: Contribution to journalArticleResearchpeer review

Rentsch, A, Landsberg, D, Brodmann, T, Bülow, L, Girbig, AK & Kalesse, M 2013, 'Synthesis and pharmacology of proteasome inhibitors', Angewandte Chemie - International Edition, vol. 52, no. 21, pp. 5450-5488. https://doi.org/10.1002/anie.201207900
Rentsch, A., Landsberg, D., Brodmann, T., Bülow, L., Girbig, A. K., & Kalesse, M. (2013). Synthesis and pharmacology of proteasome inhibitors. Angewandte Chemie - International Edition, 52(21), 5450-5488. https://doi.org/10.1002/anie.201207900
Rentsch A, Landsberg D, Brodmann T, Bülow L, Girbig AK, Kalesse M. Synthesis and pharmacology of proteasome inhibitors. Angewandte Chemie - International Edition. 2013 May 17;52(21):5450-5488. doi: 10.1002/anie.201207900
Rentsch, Andreas ; Landsberg, Dirk ; Brodmann, Tobias et al. / Synthesis and pharmacology of proteasome inhibitors. In: Angewandte Chemie - International Edition. 2013 ; Vol. 52, No. 21. pp. 5450-5488.
Download
@article{bd7cbf4b171249308ecfcc993fba0259,
title = "Synthesis and pharmacology of proteasome inhibitors",
abstract = "Shortly after the discovery of the proteasome it was proposed that inhibitors could stabilize proteins which ultimately would trigger apoptosis in tumor cells. The essential questions were whether small molecules would be able to inhibit the proteasome without generating prohibitive side effects and how one would derive these compounds. Fortunately, {"}Mother Nature{"} has generated a wide variety of natural products that provide distinct selectivities and specificities. The chemical synthesis of these natural products finally provided access to analogues and optimized drugs of which two different classes have been approved for the treatment of malignancies. Despite these achievements, additional lead structures derived from nature are under investigation and will be discussed with regard to their biological potential and chemical challenges. The ubiquitin-proteasome system controls fundamental processes such as cell cycle regulation, DNA repair, apoptosis, and immune and inflammatory responses, as well as hereditary disorders such as cystic fibrosis. This Review covers the synthesis of the most important proteasome inhibitors as well as their mode of action and clinical development.",
keywords = "antitumor agents, clinical development, inhibitors, natural products, proteasome",
author = "Andreas Rentsch and Dirk Landsberg and Tobias Brodmann and Leila B{\"u}low and Girbig, {Anna Katharina} and Markus Kalesse",
year = "2013",
month = may,
day = "17",
doi = "10.1002/anie.201207900",
language = "English",
volume = "52",
pages = "5450--5488",
journal = "Angewandte Chemie - International Edition",
issn = "1433-7851",
publisher = "John Wiley and Sons Ltd",
number = "21",

}

Download

TY - JOUR

T1 - Synthesis and pharmacology of proteasome inhibitors

AU - Rentsch, Andreas

AU - Landsberg, Dirk

AU - Brodmann, Tobias

AU - Bülow, Leila

AU - Girbig, Anna Katharina

AU - Kalesse, Markus

PY - 2013/5/17

Y1 - 2013/5/17

N2 - Shortly after the discovery of the proteasome it was proposed that inhibitors could stabilize proteins which ultimately would trigger apoptosis in tumor cells. The essential questions were whether small molecules would be able to inhibit the proteasome without generating prohibitive side effects and how one would derive these compounds. Fortunately, "Mother Nature" has generated a wide variety of natural products that provide distinct selectivities and specificities. The chemical synthesis of these natural products finally provided access to analogues and optimized drugs of which two different classes have been approved for the treatment of malignancies. Despite these achievements, additional lead structures derived from nature are under investigation and will be discussed with regard to their biological potential and chemical challenges. The ubiquitin-proteasome system controls fundamental processes such as cell cycle regulation, DNA repair, apoptosis, and immune and inflammatory responses, as well as hereditary disorders such as cystic fibrosis. This Review covers the synthesis of the most important proteasome inhibitors as well as their mode of action and clinical development.

AB - Shortly after the discovery of the proteasome it was proposed that inhibitors could stabilize proteins which ultimately would trigger apoptosis in tumor cells. The essential questions were whether small molecules would be able to inhibit the proteasome without generating prohibitive side effects and how one would derive these compounds. Fortunately, "Mother Nature" has generated a wide variety of natural products that provide distinct selectivities and specificities. The chemical synthesis of these natural products finally provided access to analogues and optimized drugs of which two different classes have been approved for the treatment of malignancies. Despite these achievements, additional lead structures derived from nature are under investigation and will be discussed with regard to their biological potential and chemical challenges. The ubiquitin-proteasome system controls fundamental processes such as cell cycle regulation, DNA repair, apoptosis, and immune and inflammatory responses, as well as hereditary disorders such as cystic fibrosis. This Review covers the synthesis of the most important proteasome inhibitors as well as their mode of action and clinical development.

KW - antitumor agents

KW - clinical development

KW - inhibitors

KW - natural products

KW - proteasome

UR - http://www.scopus.com/inward/record.url?scp=84877721642&partnerID=8YFLogxK

U2 - 10.1002/anie.201207900

DO - 10.1002/anie.201207900

M3 - Article

C2 - 23526565

AN - SCOPUS:84877721642

VL - 52

SP - 5450

EP - 5488

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

SN - 1433-7851

IS - 21

ER -

By the same author(s)